Search
Now showing items 1-5 of 5
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase
(2014)
BACKGROUND AND RATIONALE
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic ...
Monoamine oxidase inhibitory activities of heterocyclic chalcones
(2013)
Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ...
Syntheses of chalcones and 2–aminopyrimidines and their evaluation as monoamine oxidase inhibitors and as adenosine receptor antagonists
(North-West University, 2013)
Background and rationale - Parkinson’s disease is a neurodegenerative disorder characterised by reduced levels of
dopamine in the brain. The cause of Parkinson's disease is still unknown; however several theories pertaining ...
Syntheses of sulfanylphthalimide and xanthine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of adenosine receptors
(North-West University, 2013)
Currently L-DOPA is the drug most commonly used for the treatment of Parkinson’s disease (PD). However, the long-term use of L-DOPA is associated with the development of motor fluctuations and dyskinesias. Treatment mainly ...
Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase
(2015)
Parkinson’s disease is a bradykinetic disorder that is the result of the death of dopaminergic neurons in the basal ganglia of the brain. This, in turn, leads to the depletion of dopamine in the striatum, which is responsible ...